EUVIMEDEUVIMED entdecken
Fallbericht

Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series

Kazuhiro Horiuchi, Shuntaro Nakamura, Kazuki Yamada, Takashi Inoue, Kei Oiwa

Neuromuscular Disorders · 2024-06 · 39 · 37-41

DOI: 10.1016/j.nmd.2024.04.005 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neuromuscular Disorders, 2024-06. Verfasst von Kazuhiro Horiuchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hakodate Municipal Hospital, Hakodate, Japan. Electronic address: horiuchi-kazuhiro@hotmail.co.jp. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The effect of treatment with efgartigimod in seronegative myasthenia gravis (MG) remains unclear. This retrospective study aimed to evaluate symptomatic changes and safety of treatment with efgartigimod in patients with generalized MG (gMG) double-seronegative for acetylcholine receptor antibody and muscle-specific kinase antibody. We reviewed the medical records of double-seronegative gMG treated with 10 mg/kg efgartigimod once/week per cycle (4 weeks) from June 2022 to June 2023. A total of 16 patients were included. MG-activities of daily living (ADL) scores improved from 9.2 to 7.4. Mean prednisolone dose was reduced from 5.4 to 4.1 mg/day. The duration before MG-ADL deterioration after the end of a cycle was 6.1 weeks. Five patients had mild adverse events. This retrospective study revealed no significant treatment benefit in the outcomes of patients with double-seronegative gMG treated with efgartigimod.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisHumansRetrospective StudiesMaleFemaleMiddle AgedAdultAgedTreatment OutcomeActivities of Daily LivingReceptors, CholinergicAutoantibodiesPrednisolone

Stichwörter der Autor:innen

Activities of dailyCorticosteroidsEfgartigimodFcRn antagonistLivingMyasthenia gravisNeonatal Fc receptor

Substanzen

Receptors, CholinergicAutoantibodiesPrednisolone

Autor:innen und Institutionen

  • Department of Neurology, Hakodate Municipal Hospital, Hakodate, Japan. Electronic address: horiuchi-kazuhiro@hotmail.co.jp.
  • Department of Neurology, Hakodate Municipal Hospital, Hakodate, Japan.

Zitieren

APA

Horiuchi, K., Nakamura, S., Yamada, K., Inoue, T., & Oiwa, K. (2024). Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series. Neuromuscular Disorders, 39, 37-41. https://doi.org/10.1016/j.nmd.2024.04.005

Vancouver

Horiuchi K, Nakamura S, Yamada K, Inoue T, Oiwa K. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series. Neuromuscular Disorders. 2024;39:37-41. doi:10.1016/j.nmd.2024.04.005

BibTeX
@article{Horiuchi2024,
  author = {Horiuchi, Kazuhiro and Nakamura, Shuntaro and Yamada, Kazuki and Inoue, Takashi and Oiwa, Kei},
  title = {Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series},
  journal = {Neuromuscular Disorders},
  year = {2024},
  volume = {39},
  pages = {37--41},
  doi = {10.1016/j.nmd.2024.04.005}
}
Kostenlos starten →